Problem: Indian pharmaceutical industry's growth hinges on the US generics market (about US$86.9 billion), which faces intense price erosion - a threat. At the same time, USFDA crackdowns and exits by unprofitable players have triggered drug shortages, creating pricing opportunities. Companies face a strategic dilemma: cut costs and risk missing out on opportunities or invest for growth and face margin pressure. Solution: To resolve this, pharma firms must radically increase agility while improving cost efficiency. This requires unlocking hidden capacity across operations, supply chain, Quality Assurance (QA), and R&D by eliminating outdated practices. Benefits: Achieving this dual objective enables firms to respond swiftly to market opportunities without sacrificing profitability, ensuring sustained growth and competitiveness in a volatile market.

Key Takeaways

The saga of why Indian generic industry is caught in an unexpected dilemma and what it can do about it.

A pharmaceutical odyssey

Download PDF

Caught between cost-cutting and chasing growth? Learn how Indian generic pharma firms can unlock hidden capacity to navigate the volatile $86.9B US generics market.